【Bryan】評論

藥理作用相同或相反

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其血中濃度，使嚴重不良反應如神經毒性、QT延長的風險增加。如上，應為藥動學的交互作用。

【Hsin Hua Lian】評論

Diltiazem為CYP 3A4抑制劑，可能抑制Tacrolimus的代謝而升高其.....看完整詳解

【Bryan】評論

Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection.